Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis

INTRODUCTION: The major unmet need in multiple sclerosis (MS) is for neuroprotective therapies that can slow (or ideally stop) the rate of disease progression. The UK MS Society Clinical Trials Network (CTN) was initiated in 2007 with the purpose of developing a national, efficient, multiarm trial o...

Descripción completa

Detalles Bibliográficos
Autores principales: Connick, Peter, De Angelis, Floriana, Parker, Richard A, Plantone, Domenico, Doshi, Anisha, John, Nevin, Stutters, Jonathan, MacManus, David, Prados Carrasco, Ferran, Barkhof, Frederik, Ourselin, Sebastien, Braisher, Marie, Ross, Moira, Cranswick, Gina, Pavitt, Sue H, Giovannoni, Gavin, Gandini Wheeler-Kingshott, Claudia Angela, Hawkins, Clive, Sharrack, Basil, Bastow, Roger, Weir, Christopher J, Stallard, Nigel, Chandran, Siddharthan, Chataway, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119433/
https://www.ncbi.nlm.nih.gov/pubmed/30166303
http://dx.doi.org/10.1136/bmjopen-2018-021944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119433/
https://www.ncbi.nlm.nih.gov/pubmed/30166303
http://dx.doi.org/10.1136/bmjopen-2018-021944

Ejemplares similares